Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Jun;33(6):862–865. doi: 10.1128/aac.33.6.862

Effect of acyclovir on radiation- and chemotherapy-induced mouth lesions.

G J Bubley 1, B Chapman 1, S K Chapman 1, C S Crumpacker 1, L E Schnipper 1
PMCID: PMC284246  PMID: 2669626

Abstract

Several chemotherapeutic regimens and radiation therapy, if delivered to the oral mucosa, are associated with a high frequency of mouth lesions. The cause of this side effect is not known for certain, but in past studies it has sometimes been associated with the ability to culture herpes simplex virus type 1 from the mouth. In a double-blind prospective trial, patients with head and neck tumors treated with chemotherapy or radiation therapy were treated with either acyclovir or placebo. Although the frequency of culture-positive herpes simplex virus was low in the untreated group, it was significantly lower, zero, in the acyclovir-treated group. However, there were no differences in the frequency or type of mouth lesions experienced by patients receiving either radiation or chemotherapy who were taking acyclovir or placebo. These results suggest that herpes simplex virus is not a frequent cause or complication of oral lesions afflicting this patient population.

Full text

PDF
862

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson H., Scarffe J. H., Sutton R. N., Hickmott E., Brigden D., Burke C. Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial. Br J Cancer. 1984 Jul;50(1):45–49. doi: 10.1038/bjc.1984.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bader C., Crumpacker C. S., Schnipper L. E., Ransil B., Clark J. E., Arndt K., Freedberg I. M. The natural history of recurrent facial-oral infection with herpes simplex virus. J Infect Dis. 1978 Dec;138(6):897–905. doi: 10.1093/infdis/138.6.897. [DOI] [PubMed] [Google Scholar]
  3. Ervin T. J., Clark J. R., Weichselbaum R. R., Fallon B. G., Miller D., Fabian R. L., Posner M. R., Norris C. M., Jr, Tuttle S. A., Schoenfeld D. A. An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol. 1987 Jan;5(1):10–20. doi: 10.1200/JCO.1987.5.1.10. [DOI] [PubMed] [Google Scholar]
  4. Lockhart P. B., Sonis S. T. Relationship of oral complications to peripheral blood leukocyte and platelet counts in patients receiving cancer chemotherapy. Oral Surg Oral Med Oral Pathol. 1979 Jul;48(1):21–28. doi: 10.1016/0030-4220(79)90230-5. [DOI] [PubMed] [Google Scholar]
  5. Oliff A., Bleyer W. A., Poplack D. G. Methotrexate-induced oral mucositis and salivary methotrexate concentrations. Cancer Chemother Pharmacol. 1979;2(3):225–226. doi: 10.1007/BF00258300. [DOI] [PubMed] [Google Scholar]
  6. Rand K. H., Kramer B., Johnson A. C. Cancer chemotherapy associated symptomatic stomatitis: role of Herpes simplex virus (HSV). Cancer. 1982 Oct 1;50(7):1262–1265. doi: 10.1002/1097-0142(19821001)50:7<1262::aid-cncr2820500707>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  7. Saral R., Ambinder R. F., Burns W. H., Angelopulos C. M., Griffin D. E., Burke P. J., Lietman P. S. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med. 1983 Dec;99(6):773–776. doi: 10.7326/0003-4819-99-6-773. [DOI] [PubMed] [Google Scholar]
  8. Saral R., Burns W. H., Laskin O. L., Santos G. W., Lietman P. S. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med. 1981 Jul 9;305(2):63–67. doi: 10.1056/NEJM198107093050202. [DOI] [PubMed] [Google Scholar]
  9. Seifert P., Baker L. H., Reed M. L., Vaitkevicius V. K. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer. 1975 Jul;36(1):123–128. doi: 10.1002/1097-0142(197507)36:1<123::aid-cncr2820360108>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  10. Straus S. E., Seidlin M., Takiff H., Jacobs D., Bowen D., Smith H. A. Oral acyclovir to suppress recurring herpes simplex virus infections in immunodeficient patients. Ann Intern Med. 1984 Apr;100(4):522–524. doi: 10.7326/0003-4819-100-4-522. [DOI] [PubMed] [Google Scholar]
  11. Tanner N. S., Stamford I. F., Bennett A. Plasma prostaglandins in mucositis due to radiotherapy and chemotherapy for head and neck cancer. Br J Cancer. 1981 Jun;43(6):767–771. doi: 10.1038/bjc.1981.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Wade J. C., Newton B., Flournoy N., Meyers J. D. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med. 1984 Jun;100(6):823–828. doi: 10.7326/0003-4819-100-6-823. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES